SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer

Clinical Cancer Research

Volumn 21, Issue 20, 2015, Pages 4698-4708

  Zhang, Xiaotun ^a   Coleman, Ilsa M ^b   Brown, Lisha G ^a   True, Lawrence D ^c   Kollath, Lori ^a   Lucas, Jared M ^b   Lam, Hung Ming ^a   Dumpit, Ruth ^b   Corey, Eva ^a   Chéry, Lisly ^a   Lakely, Bryce ^a   Higano, Celestia S ^a,c   Montgomery, Bruce ^c   Roudier, Martine ^a   Lange, Paul H ^a,d   Nelson, Peter S ^b,c   Vessella, Robert L ^a,d   Morrissey, Colm ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN; RE1 SILENCING TRANSCRIPTION FACTOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; NERVE PROTEIN; RE1-SILENCING TRANSCRIPTION FACTOR; REPRESSOR PROTEIN; SRRM4 PROTEIN, HUMAN;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; GENE; GENE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; NEUROENDOCRINE TUMOR; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERINE ARGININE REPETITIVE MATRIX 4 GENE; SRRM4 GENE; TUMOR XENOGRAFT; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; NEUROSECRETORY CELL; PATHOLOGY; PHYSIOLOGY; PROSTATE; RNA SPLICING;

CHROMOGRANIN A; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROENDOCRINE CELLS; PHENOTYPE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; RNA SPLICING; SYNAPTOPHYSIN;

EID: 84945553181     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0157     Document Type: Article

References (37)

1. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993;71:3952-65.
2. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147-55.
3. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999;6:503-19.
4. di Sant'Agnese PA. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects. Urology 1998;51:121-4.
5. Komiya A, Yasuda K, Watanabe A, Fujiuchi Y, Tsuzuki T, Fuse H. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients. Mol Clin Oncol 2013;1:257-62.
6. McWilliam LJ, Manson C, George NJ. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997;80:287-90.
7. di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-61.
8. Aprikian AG, Cordon-Cardo C, Fair WR, Zhang ZF, Bazinet M, Hamdy SM, et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 1994;151:914-9.
9. Perrot V. Neuroendocrine differentiation in the progression of prostate cancer: an update on recent developments. Open J Urol 2012;2:173-82.
10. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 2007;10:6-14.
11. Raj B, O'Hanlon D, Vessey JP, Pan Q, Ray D, Buckley NJ, et al. Crossregulation between an alternative splicing activator and a transcription repressor controls neurogenesis. Mol Cell 2011;43:843-50.
12. Bruce AW, Donaldson IJ, Wood IC, Yerbury SA, Sadowski MI, Chapman M, et al. Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc Natl Acad Sci U S A 2004;101:10458-63.
13. Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, et al. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res 2013;28:333-40.
14. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003;55:239-46.
15. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010;120: 4478-92.
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
17. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
18. Goulburn AL, Alden D, Davis RP, Micallef SJ, Ng ES, Yu QC, et al. A targeted NKX2.1 human embryonic stem cell reporter line enables identification of human basal forebrain derivatives. Stem Cells 2011;29:462-73.
19. Isogai E, Ohira M, Ozaki T, Oba S, Nakamura Y, Nakagawara A. Oncogenic LMO3 collaborates with HEN2 to enhance neuroblastoma cell growth through transactivation of Mash1. PLoS ONE 2011;6:e19297.
20. Zhu J, Garcia-Barcelo MM, Tam PK, Lui VC. HOXB5 cooperates with NKX2-1 in the transcription of human RET. PLoS ONE 2011;6:e20815.
21. Clegg N, Ferguson C, True LD, Arnold H, Moorman A, Quinn JE, et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 2003;55:55-64.
22. Ball DW. Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett 2004;204:159-69.
23. Gupta A, Yu X, Case T, Paul M, Shen MM, Kaestner KH, et al. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2. Prostate 2013;73:582-9.
24. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate 2006; 66:1013-28.
25. Hu Y, Wang T, Stormo GD, Gordon JI. RNA interference of achaete-scute homolog 1 in mouse prostate neuroendocrine cells reveals its gene targets and DNA binding sites. Proc Natl Acad Sci U S A 2004;101: 5559-64.
26. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 2005;24:7073-83.
27. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, et al. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol 2002;161:705-15.
28. Calarco JA, Superina S, O'Hanlon D, Gabut M, Raj B, Pan Q, et al. Regulation of vertebrate nervous system alternative splicing and development by an SR-related protein. Cell 2009;138:898-910.
29. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014;38:756-67.
30. Zhang T, Armstrong AJ. Clinical phenotypes of castration-resistant prostate cancer. Clin Adv Hematol Oncol 2013;11:707-18.
31. Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 2014;4:60.
32. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 2014;20:2846-50.
33. Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A, et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res 2014;42:999-1015.
34. Liang H, Studach L, Hullinger RL, Xie J, Andrisani OM. Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25. Exp Cell Res 2014;320:188-99.
35. Zhu Y, Liu C, Cui Y, Nadiminty N, Lou W, Gao AC. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate 2014;74:1086-94.
36. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, et al. From sequence to molecular pathology, and amechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012;227:286-97.
37. Krauss DJ, Hayek S, Amin M, Ye H, Kestin LL, Zadora S, et al. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 2011;81:e119-e125.